The University of Nevada, Reno School of Medicine

Spotlight on IL-13: Long-Term Strategies in the Management of Moderate-to-Severe Atopic Dermatitis

MD, MBA

Recognize the burden of itch in chronic, recurrent flares in moderate-to-severe atopic dermatitis (AD) despite topical corticosteroid use

Identify patients with moderate-to-severe AD eligible for biologic therapy according to the 2023 American Academy of Dermatology guidelines 

Examine strategies to optimize the use of IL-13 biologics for the long-term management of moderate-to-severe AD 

Atopic dermatitis (AD) is a chronic, relapsing inflammatory dermatosis characterized by epidermal barrier dysfunction, type 2–skewed immune activation, and intense pruritus with eczematous lesions. Disease expression varies by age and severity, with recurrent flares and a well-established association with atopic comorbidities including asthma, allergic rhinitis, and food allergy.

This hub gathers the evidence, expert perspective, and practical insight shaping how atopic dermatitis is understood and treated today, connecting emerging therapies with the everyday decisions that define long-term care.

PANP25: Spotlight on IL-13: Long-Term Strategies in the Management of Moderate-to-Severe Atopic Dermatitis

About

Learning Objectives

Intended Audience

Faculty

Accreditation Statement

Credit Designation Statement

Disclosures